Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. Recently, we have significantly expanded our commercial platform in China and launched our own direct sales team. We are working to expand our portfolio through in-licensing, partnering or acquisition, and recently acquired the commercial rights to the ventilator-compatible nitric oxide product AirNOvent* in the US and China.
Our asthma management products
Our market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States, United Kingdom, China and Germany. Our NIOX® products are also supplied in many other countries through our international network of partners.
Our US commercial collaboration
We collaborate with AstraZeneca in the United States, where we currently promote the COPD product Tudorza® and anticipate taking full control of this product in 2019 following the recent exercise of our option. We also have the US commercial rights to Duaklir®**, for which a New Drug Application was submitted in Q2 2018.
Our AirNOvent partnership
In early 2019, we acquired the exclusive commercial rights to ventilator-compatible nitric oxide product AirNOvent in the US and China from AIT Therapeutics Inc. AIT plans to submit the product for approval in the United States in the coming months for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn.
Our respiratory pipeline
Our lead asthma product targets substitution of GSK’s Flixotide® pMDI, and we have a product candidate targeting direct substitution of Seretide® pMDI. We also have a number of chronic obstructive pulmonary disease treatment candidates, including novel formulations of currently approved drugs and a substitute for Spiriva Handihaler®. We are seeking development partners for our pipeline products as part of our commercially-focused investment strategy.
Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange. In June 2015, we completed the acquisitions of Aerocrine and Prosonix as part of our strategy to independently commercialize our products and broaden our pipeline, and in April 2017 we established a commercial collaboration with AstraZeneca in the United States. In January 2019, we acquired the commercial rights to AirNOvent in the US and China, and in February 2019 we completed the move of the Company’s shares to AIM where they are quoted under CIR.